-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cardiovascular disease (CVD) is caused by heart and vascular diseases, including coronary heart disease (heart disease), cerebrovascular disease (stroke), elevated blood pressure (hypertension), peripheral arterial disease, rheumatic heart disease , congenital heart disease and heart failure
.
It is understood that cardiovascular disease has now become a major public health problem facing the world
.
It is understood that there are many types of cardiovascular drugs, mainly anti-hypertensive drugs, anti-angina pectoris and arrhythmia drugs, anti-heart failure drugs, lipid-lowering drugs, anti-platelet and anti-coagulation drugs, drugs that improve circulation and improve myocardial metabolism
.
With the increasing number of patients with various types of cardiovascular diseases, the industry believes that the cardiovascular drug market will begin to continue to grow
.
According to a forecast data released by Globaldata, the total sales of cardiovascular disease drugs in the future will increase steadily, from nearly 47 billion in 2018 to more than 70 billion in 2024
.
It is worth mentioning that in the context of the continuous expansion of the entire cardiovascular drug market, more and more pharmaceutical companies are also accelerating the deployment of various cardiovascular drug fields
.
Recently, Skyline Therapeutics Co.
, Ltd.
(Skyline Therapeutics, hereinafter referred to as "Nine-Day Bio", the original Geneception), and BioMarin announced that they have reached a multi-year global strategic cooperation to jointly research and develop adeno-associated virus (AAV) ) New gene therapy for the treatment of hereditary cardiovascular diseases
.
This strategic cooperation will mainly use Jiutian Biology’s integrated AAV gene therapy R&D and production system, including its independent research and development of innovative viral vector design and construction technology and advanced production capabilities, aimed at genetic dilated cardiomyopathy ( DCM) to develop innovative gene therapy
.
In fact, the huge and steadily growing cardiovascular therapy market is currently attracting more and more attention from domestic and foreign pharmaceutical companies
.
In addition to Jiutian Bio-Pharmaceutical Co.
, Ltd.
, in March this year, Hengrui Medicine also received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration, and approved the marketing of tolvaptan tablets.
.
Tolvaptan is a selective and competitive vasopressin V2 receptor antagonist, suitable for the treatment of clinically obvious hypervolemic and normal volume hyponatremia, including those with heart failure, liver cirrhosis and Patients with syndrome of abnormal secretion of antidiuretic hormone; used for loop diuretics and other diuretics to treat body fluid retention caused by heart failure where the effect of other diuretics is unsatisfactory
.
Data show that in 2020, the sales of terminal tolvaptan tablets in public medical institutions in China will exceed 200 million yuan
.
At present, there are 3 manufacturers of tolvaptan tablets, Otsuka Pharmaceutical, Jiangsu Hengrui Pharmaceutical, and Nanjing Chia Tai Tianqing Pharmaceutical
.
On the whole, the current cardiovascular disease treatment market has become relatively mature and fiercely competitive, but with the rapid increase in the number of cardiovascular disease patients and the demand for continuous medication for most cardiovascular diseases that cannot be completely cured, the analysis believes that, This field will also be full of unmet needs and huge market development space
.
In this context, the industry predicts that companies in the pharmaceutical industry with high-quality generic and innovative drug R&D capabilities may be expected to obtain more new opportunities in the future
.
.
It is understood that cardiovascular disease has now become a major public health problem facing the world
.
It is understood that there are many types of cardiovascular drugs, mainly anti-hypertensive drugs, anti-angina pectoris and arrhythmia drugs, anti-heart failure drugs, lipid-lowering drugs, anti-platelet and anti-coagulation drugs, drugs that improve circulation and improve myocardial metabolism
.
With the increasing number of patients with various types of cardiovascular diseases, the industry believes that the cardiovascular drug market will begin to continue to grow
.
According to a forecast data released by Globaldata, the total sales of cardiovascular disease drugs in the future will increase steadily, from nearly 47 billion in 2018 to more than 70 billion in 2024
.
It is worth mentioning that in the context of the continuous expansion of the entire cardiovascular drug market, more and more pharmaceutical companies are also accelerating the deployment of various cardiovascular drug fields
.
Recently, Skyline Therapeutics Co.
, Ltd.
(Skyline Therapeutics, hereinafter referred to as "Nine-Day Bio", the original Geneception), and BioMarin announced that they have reached a multi-year global strategic cooperation to jointly research and develop adeno-associated virus (AAV) ) New gene therapy for the treatment of hereditary cardiovascular diseases
.
This strategic cooperation will mainly use Jiutian Biology’s integrated AAV gene therapy R&D and production system, including its independent research and development of innovative viral vector design and construction technology and advanced production capabilities, aimed at genetic dilated cardiomyopathy ( DCM) to develop innovative gene therapy
.
In fact, the huge and steadily growing cardiovascular therapy market is currently attracting more and more attention from domestic and foreign pharmaceutical companies
.
In addition to Jiutian Bio-Pharmaceutical Co.
, Ltd.
, in March this year, Hengrui Medicine also received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration, and approved the marketing of tolvaptan tablets.
.
Tolvaptan is a selective and competitive vasopressin V2 receptor antagonist, suitable for the treatment of clinically obvious hypervolemic and normal volume hyponatremia, including those with heart failure, liver cirrhosis and Patients with syndrome of abnormal secretion of antidiuretic hormone; used for loop diuretics and other diuretics to treat body fluid retention caused by heart failure where the effect of other diuretics is unsatisfactory
.
Data show that in 2020, the sales of terminal tolvaptan tablets in public medical institutions in China will exceed 200 million yuan
.
At present, there are 3 manufacturers of tolvaptan tablets, Otsuka Pharmaceutical, Jiangsu Hengrui Pharmaceutical, and Nanjing Chia Tai Tianqing Pharmaceutical
.
On the whole, the current cardiovascular disease treatment market has become relatively mature and fiercely competitive, but with the rapid increase in the number of cardiovascular disease patients and the demand for continuous medication for most cardiovascular diseases that cannot be completely cured, the analysis believes that, This field will also be full of unmet needs and huge market development space
.
In this context, the industry predicts that companies in the pharmaceutical industry with high-quality generic and innovative drug R&D capabilities may be expected to obtain more new opportunities in the future
.
